DAmico A, Scuderi S, Saccone S, Castorina A, Drago F, DAgata V
J Mol Neurosci. 2013; 51(2):503-13.
PMID: 23900722
DOI: 10.1007/s12031-013-0076-7.
Ng S, Chow B, Kasamatsu J, Kasahara M, Lee L
PLoS One. 2012; 7(9):e44691.
PMID: 22957100
PMC: 3434177.
DOI: 10.1371/journal.pone.0044691.
Gozes I
J Mol Neurosci. 2008; 36(1-3):115-24.
PMID: 18607776
DOI: 10.1007/s12031-008-9105-3.
Ceraudo E, Tan Y, Nicole P, Couvineau A, Laburthe M
J Mol Neurosci. 2008; 36(1-3):245-8.
PMID: 18597186
DOI: 10.1007/s12031-008-9073-7.
Couvineau A, Robert J, Ramdani T, Lacapere J, Rouyer-Fessard C, Laburthe M
J Mol Neurosci. 2008; 36(1-3):249-53.
PMID: 18592417
DOI: 10.1007/s12031-008-9072-8.
Effects of PACAP and VIP on cAMP-generating system and proliferation of C6 glioma cells.
Sokolowska P, Nowak J
J Mol Neurosci. 2008; 36(1-3):286-91.
PMID: 18491045
DOI: 10.1007/s12031-008-9071-9.
The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics.
Ceraudo E, Murail S, Tan Y, Lacapere J, Neumann J, Couvineau A
Mol Endocrinol. 2007; 22(1):147-55.
PMID: 17885205
PMC: 5419634.
DOI: 10.1210/me.2007-0361.
Neuroprotection against neurodegenerative diseases: development of a novel hybrid neuroprotective peptide Colivelin.
Chiba T, Nishimoto I, Aiso S, Matsuoka M
Mol Neurobiol. 2007; 35(1):55-84.
PMID: 17519506
NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).
Gozes I, Morimoto B, Tiong J, Fox A, Sutherland K, Dangoor D
CNS Drug Rev. 2006; 11(4):353-68.
PMID: 16614735
PMC: 6741706.
DOI: 10.1111/j.1527-3458.2005.tb00053.x.
Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.
Zawilska J, Dejda A, Niewiadomski P, Gozes I, Nowak J
J Mol Neurosci. 2005; 25(3):215-24.
PMID: 15800375
DOI: 10.1385/JMN:25:3:215.
From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division.
Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman D, Spier A
J Mol Neurosci. 2003; 20(3):315-22.
PMID: 14501014
DOI: 10.1385/JMN:20:3:315.
Antagonism of VIP-stimulated cyclic AMP formation in chick brain.
Nowak J, Sedkowska P, Zawilska J, Gozes I, Brenneman D
J Mol Neurosci. 2003; 20(2):163-72.
PMID: 12794310
DOI: 10.1385/JMN:20:2:163.
Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors in chick cerebral cortex.
Zawilska J, Niewiadomski P, Nowak J
J Mol Neurosci. 2003; 20(2):153-62.
PMID: 12794309
DOI: 10.1385/JMN:20:2:153.
NAP accelerates the performance of normal rats in the water maze.
Gozes I, Alcalay R, Giladi E, Pinhasov A, Furman S, Brenneman D
J Mol Neurosci. 2002; 19(1-2):167-70.
PMID: 12212775
DOI: 10.1007/s12031-002-0028-0.
Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide-stimulated cyclic AMP synthesis in rat cerebral cortical slices: interaction with noradrenaline, adrenaline, and forskolin.
Nowak J, Kuba K
J Mol Neurosci. 2002; 18(1-2):47-52.
PMID: 11931349
DOI: 10.1385/JMN:18:1-2:47.
A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: gene Atlas array analysis.
Romano J, Beni-Adani L, Nissenbaum O, Brenneman D, Shohami E, Gozes I
J Mol Neurosci. 2002; 18(1-2):37-45.
PMID: 11931348
DOI: 10.1385/JMN:18:1-2:37.
(N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Moody T, Jensen R, Fridkin M, Gozes I
J Mol Neurosci. 2002; 18(1-2):29-35.
PMID: 11931347
DOI: 10.1385/JMN:18:1-2:29.
